Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (30)
Jaco Voorham, Simonetta Baldi, Luigi Santoro, Marjan Kerkhof, Marco Contoli, Leonardo M Fabbri, Huib A M Kerstjens, Jose Luis López-Campos, Nicolas Roche, Dave Singh, Claus F Vogelmeier & David B Price. (2020) Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2739-2750.
Read now
Read now
Tanja Plate, Felix W Friedrich & Jutta Beier. (2020) Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1335-1347.
Read now
Read now
Sateesh Sakhamuri & Terence Seemungal. (2020) COPD: Gaps in the GOLD Recommendations and Related Imperative Research Needs. COPD: Journal of Chronic Obstructive Pulmonary Disease 17:1, pages 1-3.
Read now
Read now
Birsen Pinar Yildiz, Mesut Bayraktaroglu & Hakan Gunen. (2019) Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. Current Medical Research and Opinion 35:12, pages 2187-2196.
Read now
Read now
Fernando J Martinez, Roger A Abrahams, Gary T Ferguson, Leif Bjermer, Lars Grönke, Florian Voß & Dave Singh. (2019) Effects of baseline symptom burden on treatment response in COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 181-194.
Read now
Read now
Chitra Lal & Charlie Strange. (2017) A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opinion on Pharmacotherapy 18:17, pages 1833-1843.
Read now
Read now
Mike Thomas, David MG Halpin & Marc Miravitlles. (2017) When is dual bronchodilation indicated in COPD?. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2291-2305.
Read now
Read now
David Price, Anders Østrem, Mike Thomas & Tobias Welte. (2017) Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 141-168.
Read now
Read now
Dejan Radovanovic, Marco Mantero, Giuseppe Francesco Sferrazza Papa, Vincenzo Valenti, Stefano Aliberti, Fabiano Di Marco & Pierachille Santus. (2016) Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 10:10, pages 1045-1055.
Read now
Read now
Yasuhiro Yamauchi, Hideo Yasunaga, Wakae Hasegawa, Yukiyo Sakamoto, Hideyuki Takeshima, Taisuke Jo, Hiroki Matsui, Kiyohide Fushimi & Takahide Nagase. (2016) Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 1403-1411.
Read now
Read now
Subhabrata Moitra, Arvind B Bhome & Bill B Brashier. (2015) Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Design, Development and Therapy 9, pages 1989-1999.
Read now
Read now
Andrea S Melani. (2015) Long-acting muscarinic antagonists. Expert Review of Clinical Pharmacology 8:4, pages 479-501.
Read now
Read now
Wijdan H Ramadan, Wissam K Kabbara, Ghada M El Khoury & Sarah A Al Assir. (2015) Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2347-2356.
Read now
Read now
Eline L Huisman, Sarah M Cockle, Afisi S Ismaila, Andreas Karabis & Yogesh Suresh Punekar. (2015) Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1863-1881.
Read now
Read now
Chitra Lal & Charlie Strange. (2015) Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:3, pages 427-434.
Read now
Read now
Charlotte Suppli Ulrik. (2014) Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 331-338.
Read now
Read now
Walter Vincken, Joseph Aumann, Hungta Chen, Michelle Henley, Danny McBryan & Pankaj Goyal. (2014) Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 215-228.
Read now
Read now
Emer Kelly. (2014) Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology 7:4, pages 403-413.
Read now
Read now
Annette J Theron, Helen C Steel, Gregory R Tintinger, Charles Feldman & Ronald Anderson. (2013) Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?. Drug Design, Development and Therapy 7, pages 1387-1398.
Read now
Read now
Ruben D Restrepo, Andrew Tate & Joshua Coquat. (2013) Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 14:14, pages 1993-2002.
Read now
Read now
Samuel Louie, Amir A Zeki, Michael Schivo, Andrew L Chan, Ken Y Yoneda, Mark Avdalovic, Brian M Morrissey & Timothy E Albertson. (2013) The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Review of Clinical Pharmacology 6:2, pages 197-219.
Read now
Read now
Anthony D'Urzo & Claus Vogelmeier. (2012) Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine 6:3, pages 285-299.
Read now
Read now
Edward M. Kerwin, Anthony D. D'Urzo, Arthur F. Gelb, Hassan Lakkis, Esther Garcia Gil & Cynthia F. Caracta. (2012) Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I). COPD: Journal of Chronic Obstructive Pulmonary Disease 9:2, pages 90-101.
Read now
Read now
Jutta Beier, Jan van Noord, Amanda Deans, Jean Brooks, Claire Maden, Suus Baggen, Rashmi Mehta & Anthony Cahn. (2012) Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 153-164.
Read now
Read now
Edward J Mills, Eric Druyts, Isabella Ghement & Milo A Puhan. (2011) Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clinical Epidemiology 3, pages 107-129.
Read now
Read now
Peter J Barnes. (2011) Triple inhalers for obstructive airways disease: will they be useful?. Expert Review of Respiratory Medicine 5:3, pages 297-300.
Read now
Read now
Boudewijn Van de Maele, Leonardo M. Fabbri, Carmen Martin, Rachael Horton, Michael Dolker & Tim Overend. (2010) Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:6, pages 418-427.
Read now
Read now
Nicholas J Gross & James F Donohue. (2010) Nebulized formoterol: a review of clinical efficacy and safety in COPD. International Journal of Chronic Obstructive Pulmonary Disease 5, pages 223-232.
Read now
Read now
Satomi Onoue, Shingen Misaka, Yohei Kawabata & Shizuo Yamada. (2009) New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opinion on Drug Delivery 6:8, pages 793-811.
Read now
Read now
Mario Cazzola & Donald P. Tashkin. (2009) Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function. COPD: Journal of Chronic Obstructive Pulmonary Disease 6:5, pages 404-415.
Read now
Read now
Articles from other publishers (81)
Amir Bar-Shai, Ophir Freund, Tal Ovdat, Michael J. Segel, Robert Klempfner & Avishay Elis. (2023) Management of acute COPD exacerbations in the internal medicine departments in Israel–a national survey. Frontiers in Medicine 10.
Crossref
Crossref
Shubham Thakur, Navid Reza Shahtaghi, Manjot Kaur, Riya Shivgotra & Subheet Kumar Jain. 2023. Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases. Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases
235
244
.
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
Sundeep Salvi, ManishK Jain, Srikanth Krishnamurthy, Akash Balki, Rahul Kodgule, Monika Tandon, Sagar Bhagat, Sagar Panchal, Nishtha Khatri, Wen Wu, Amol Pendse, Saiprasad Patil & Hanmant Barkate. (2022) Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD. Lung India 39:6, pages 517.
Crossref
Crossref
Tonio Pera, Cali Loblundo & Raymond B. Penn. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
762
802
.
Katharina Marth, Andreas Renner & Wolfgang Pohl. (2021) TRICOP – A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD. Respiratory Medicine 182, pages 106398.
Crossref
Crossref
Mohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. MadneyMohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. Madney. 2021. Essentials of Aerosol Therapy in Critically ill Patients. Essentials of Aerosol Therapy in Critically ill Patients
169
188
.
Maher Khdour, Hussein Hallak & Hani Abdeen. 2021. Handbook of Healthcare in the Arab World. Handbook of Healthcare in the Arab World
2807
2826
.
Bernardino Alcázar-Navarrete & Jose Luis Lopez-Campos. (2020) Comparaciones entre asociaciones de broncodilatadores de larga duración para la enfermedad pulmonar obstructiva crónica. Open Respiratory Archives 2:4, pages 289-293.
Crossref
Crossref
Enrica Di Martino, Alessio Provenzani & Piera Polidori. (2020) Evidence-based application of explicit criteria to assess the appropriateness of geriatric prescriptions at admission and hospital stay. PLOS ONE 15:8, pages e0238064.
Crossref
Crossref
Kaiser Jehan Peerzada. 2020. Chronic Lung Diseases. Chronic Lung Diseases
157
180
.
Riju Ray, Beth Hahn, Richard H. Stanford, John White, Breanna Essoi & Alyssa Goolsby Hunter. (2019) Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study. Pulmonary Therapy 5:2, pages 191-200.
Crossref
Crossref
Beth Hahn, Richard H. Stanford, Alyssa Goolsby Hunter, Breanna Essoi, John White & Riju Ray. (2019) Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. Pulmonary Therapy 5:1, pages 69-80.
Crossref
Crossref
Mario Malerba, Valentina Foci, Filippo Patrucco, Patrizia Pochetti, Matteo Nardin, Corrado Pelaia & Alessandro Radaeli. (2019) Single Inhaler LABA/LAMA for COPD. Frontiers in Pharmacology 10.
Crossref
Crossref
Aziz A. Ansari, Daniel H. Pomerantz, Robert L. Jayes, Eric A. Aguirre & Rachel D. Havyer. (2018) Promoting Primary Palliative Care in Severe Chronic Obstructive Pulmonary Disease: Symptom Management and Preparedness Planning. Journal of Palliative Care 34:2, pages 85-91.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Maher Khdour, Hussein Hallak & Hani Abdeen. 2019. Handbook of Healthcare in the Arab World. Handbook of Healthcare in the Arab World
1
21
.
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa & Gregory Feldman. (2018) Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulmonary Therapy 4:2, pages 171-183.
Crossref
Crossref
Na Yu, Yi-Tian Sun, Xin-Ming Su, Miao He, Bing Dai & Jian Kang. (2018) Treatment with eucalyptol mitigates cigarette smoke-induced lung injury through suppressing ICAM-1 gene expression. Bioscience Reports 38:4.
Crossref
Crossref
James F. Donohue, Paul W. Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, David G. Morris, Francesco Patalano & Robert Fogel. (2018) Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 49, pages 11-19.
Crossref
Crossref
Takashi Makino, Hajime Otsuka, Yoshinobu Hata, Satoshi Koezuka, Yoko Azuma, Kazutoshi Isobe, Keishi Sugino, Satoru Ebihara, Sakae Homma & Akira Iyoda. (2018) Long‑acting muscarinic antagonist and long‑acting β2‑agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery. Molecular and Clinical Oncology.
Crossref
Crossref
Yong Zou, Jian Xiao, Xiao Xiao Lu, Zi An Xia, Bin Xie, Jun Li & Qiong Chen. (2018) Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis. The Clinical Respiratory Journal 12:1, pages 269-278.
Crossref
Crossref
Donald Banerji, Robert Fogel & Francesco Patalano. (2018) Indacaterol/glycopyrronium: a dual bronchodilator for COPD. Drug Discovery Today 23:1, pages 196-203.
Crossref
Crossref
Fernando J. Martinez, Leonardo M. Fabbri, Gary T. Ferguson, Chad Orevillo, Patrick Darken, Ubaldo J. Martin & Colin Reisner. (2017) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest 152:6, pages 1169-1178.
Crossref
Crossref
Katya Y. J. Sion, Eline L. Huisman, Yogesh S. Punekar, Ian Naya & Afisi S. Ismaila. (2017) A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD. Pulmonary Therapy 3:2, pages 297-316.
Crossref
Crossref
Joachim H. Ficker, Klaus F. Rabe & Tobias Welte. (2017) Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology & Therapeutics 45, pages 19-33.
Crossref
Crossref
Luigino Calzetta, Paola Rogliani, Josuel Ora, Ermanno Puxeddu, Mario Cazzola & Maria Gabriella Matera. (2017) LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review 26:143, pages 160043.
Crossref
Crossref
Kazuhisa Asai, Kazuto Hirata, Shu Hashimoto, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Kimitoshi Ikeda, Robert Fogel & Donald Banerji. (2016) Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE. Respiratory Investigation 54:6, pages 428-435.
Crossref
Crossref
Graham Cope. (2016) Comparing the range and costs of COPD treatments in primary care. Practice Nursing 27:9, pages 417-422.
Crossref
Crossref
Graham Cope. (2016) Cost-effectively prescribing treatments for managing COPD. Nurse Prescribing 14:6, pages 278-284.
Crossref
Crossref
Graham Cope. (2016) Cost-effectiveness of treatments for COPD. British Journal of Healthcare Management 22:1, pages 10-15.
Crossref
Crossref
Sae Ahm KimJi-Hyun LeeEun-Kyung KimTae-Hyung KimWoo Jin KimJin Hwa LeeHo Il YoonSeunghee BaekJae Seung LeeYeon-Mok OhSang-Do Lee. (2016) Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD. Tuberculosis and Respiratory Diseases 79:1, pages 22.
Crossref
Crossref
Hugo A Farne & Christopher J Cates. (2015)
Long-acting beta
2
-agonist in addition to tiotropium versus either tiotropium or long-acting beta
2
-agonist alone for chronic obstructive pulmonary disease
. Cochrane Database of Systematic Reviews 2015:10.
Crossref
Crossref
Björn Laudahn & Sören Schmidtmann. (2015) Wie praxisrelevant sind die GOLD-Empfehlungen für den ambulanten Alltag bei COPD?. Pneumo News 7:5, pages 53-59.
Crossref
Crossref
Alejandra L?pez-Giraldo, Robert Rodr?guez-Roisin & Alvar Agust?. (2015) Enfermedad pulmonar obstructiva cr?nica: la d?cada prodigiosa. Implicaciones para su diagn?stico, prevenci?n y tratamiento. Medicina Cl?nica 144:11, pages 507-513.
Crossref
Crossref
Alejandra López-Giraldo, Robert Rodríguez-Roisin & Alvar Agustí. (2015) Chronic obstructive pulmonary disease: The golden decade. Implications for the diagnosis, prevention and treatment of chronic obstructive pulmonary disease. Medicina Clínica (English Edition) 144:11, pages 507-513.
Crossref
Crossref
Dave Singh. (2015) New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. British Journal of Clinical Pharmacology 79:5, pages 695-708.
Crossref
Crossref
Prescott G Woodruff, Alvar Agusti, Nicolas Roche, Dave Singh & Fernando J Martinez. (2015) Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. The Lancet 385:9979, pages 1789-1798.
Crossref
Crossref
R. Buhl, C. Gessner, W. Schuermann, K. Foerster, C. Sieder, S. Hiltl & S. Korn. (2015) Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 70:4, pages 311-319.
Crossref
Crossref
Brian R. Leaker, Peter J. Barnes, C. Richard Jones, Ahmet Tutuncu & Dave Singh. (2015) Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology 79:3, pages 492-500.
Crossref
Crossref
Makoto Hoshino, Junichi Ohtawa & Kenta Akitsu. (2015) Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair® in chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 30, pages 128-133.
Crossref
Crossref
Anthony D D’Urzo, Stephen I Rennard, Edward M Kerwin, Victor Mergel, Anne R Leselbaum & Cynthia F Caracta. (2014) Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respiratory Research 15:1.
Crossref
Crossref
M. Reza Maleki-Yazdi, Thomas Kaelin, Nathalie Richard, Michael Zvarich & Alison Church. (2014) Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial. Respiratory Medicine 108:12, pages 1752-1760.
Crossref
Crossref
Jadwiga A. Wedzicha, Ronald Dahl, Roland Buhl, Agnes Schubert-Tennigkeit, Hungta Chen, Peter D'Andrea, Robert Fogel & Donald Banerji. (2014) Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respiratory Medicine 108:10, pages 1498-1507.
Crossref
Crossref
Donald Banerji, Robert Fogel & Kai-Michael Beeh. (2014) Dual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of the latest clinical data. Clinical Investigation 4:6, pages 511-533.
Crossref
Crossref
Bartolome Celli, Glenn Crater, Sally Kilbride, Rashmi Mehta, Maggie Tabberer, Chris J. Kalberg & Alison Church. (2014) Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD. Chest 145:5, pages 981-991.
Crossref
Crossref
Makoto Hoshino & Junichi Ohtawa. (2014) Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology 19:3, pages 403-410.
Crossref
Crossref
Kayleigh M Kew, Sofia Dias & Christopher J Cates. (2014) Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Clare L. Ross & Trevor T. Hansel. (2014) New Drug Therapies for COPD. Clinics in Chest Medicine 35:1, pages 219-239.
Crossref
Crossref
Yu-Il Kim. (2014) Chronic Obstructive Pulmonary Disease: Respiratory Review of 2013. Tuberculosis and Respiratory Diseases 76:2, pages 53.
Crossref
Crossref
Fulvio Braido, Ilaria Baiardini, Mario Cazzola, Guy Brusselle, Fiorenza Marugo & Giorgio Walter Canonica. (2013) Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD. Respiratory Medicine 107:10, pages 1465-1480.
Crossref
Crossref
C. Compton, D. McBryan, E. Bucchioni & F. Patalano. (2013) The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 26:5, pages 562-573.
Crossref
Crossref
Donald P Tashkin. (2013) Tiotropium for the treatment of chronic obstructive pulmonary disease. Clinical Practice 10:2, pages 141-155.
Crossref
Crossref
Claus F Vogelmeier, Eric D Bateman, John Pallante, Vijay KT Alagappan, Peter D'Andrea, Hungta Chen & Donald Banerji. (2013) Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. The Lancet Respiratory Medicine 1:1, pages 51-60.
Crossref
Crossref
Jørgen Vestbo, Suzanne S. Hurd, Alvar G. Agustí, Paul W. Jones, Claus Vogelmeier, Antonio Anzueto, Peter J. Barnes, Leonardo M. Fabbri, Fernando J. Martinez, Masaharu Nishimura, Robert A. Stockley, Don D. Sin & Roberto Rodriguez-Roisin. (2013) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 187:4, pages 347-365.
Crossref
Crossref
Donald P Tashkin & Gary T Ferguson. (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research 14:1, pages 49.
Crossref
Crossref
Charlotta Karner, Jimmy Chong & Phillippa Poole. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Mario Cazzola, Clive P. Page, Luigino Calzetta & M. Gabriella Matera. (2012) Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews 64:3, pages 450-504.
Crossref
Crossref
Sharon R. Rosenberg & Ravi Kalhan. (2012) An Integrated Approach to the Medical Treatment of Chronic Obstructive Pulmonary Disease. Medical Clinics of North America 96:4, pages 811-826.
Crossref
Crossref
Mario Malerba, Alessandro Radaeli & Jaymin B. Morjaria. (2012) Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discovery Today 17:9-10, pages 496-504.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. 2012. Advances in Combination Therapy for Asthma and COPD. Advances in Combination Therapy for Asthma and COPD
81
101
.
Wen‐Hui Zhang, Yong Zhang, Yong‐Yao Cui, Wei‐Fang Rong, Carole Cambier, Philippe Devillier, Fabrice Bureau, Charles Advenier & Pascal Gustin. (2011)
Can β
2
‐adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
. Fundamental & Clinical Pharmacology 26:1, pages 118-134.
Crossref
Crossref
Gustavo J. Rodrigo, Vicente Plaza & Jos? A. Castro-Rodr?guez. (2012) Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review. Pulmonary Pharmacology & Therapeutics 25:1, pages 40-47.
Crossref
Crossref
Thys van der Molen & Mario Cazzola. (2012) Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Primary Care Respiratory Journal 21:1, pages 101-108.
Crossref
Crossref
Teresa A. Schweiger. (2012) Present and Prospective Therapeutic Regimens for COPD. Clinical Medicine Insights: Therapeutics 4, pages CMT.S2106.
Crossref
Crossref
Peter J BarnesStephanie KornRoland Buhl. 2012. Addressing Unmet Medical Needs in COPD Management. Addressing Unmet Medical Needs in COPD Management
76
87
.
Gillian M. Keating. (2012) Tiotropium Bromide Inhalation Powder. Drugs 72:2, pages 273-300.
Crossref
Crossref
Nicola A. Hanania, Glenn D. Crater, Andrea N. Morris, Amanda H. Emmett, Dianne M. O’Dell & Dennis E. Niewoehner. (2012) Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine 106:1, pages 91-101.
Crossref
Crossref
Marie Westwood, Jean Bourbeau, Paul W Jones, Annamaria Cerulli, Gorana Capkun-Niggli & Gill Worthy. (2011) Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory Research 12:1.
Crossref
Crossref
A. Agusti, J. Hedner, J.M. Marin, F. Barbé, M. Cazzola & S. Rennard. (2011) Night-time symptoms: a forgotten dimension of COPD. European Respiratory Review 20:121, pages 183-194.
Crossref
Crossref
Claus Vogelmeier & Donald Banerji. (2011) NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 5:3, pages 163-173.
Crossref
Crossref
Jianmiao WANG, Di JIN, Peng ZUO, Tao WANG, Yongjian XU & Weining XIONG. (2011) Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: A meta-analysis. Respirology 16:2, pages 350-358.
Crossref
Crossref
Donald P. Tashkin & Santosh T. Varghese. (2011) Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulmonary Pharmacology & Therapeutics 24:1, pages 147-152.
Crossref
Crossref
Donald P Tashkin & Leonardo M Fabbri. (2010) Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respiratory Research 11:1.
Crossref
Crossref
Danilo C. Berton, Michel Reis, Ana Cristina B. Siqueira, Adriano C. Barroco, Luciana S. Takara, Daniela M. Bravo, Solange Andreoni & J. Alberto Neder. (2010) Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respiratory Medicine 104:9, pages 1288-1296.
Crossref
Crossref
Mario Cazzola & Mathieu Molimard. (2010) The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology & Therapeutics 23:4, pages 257-267.
Crossref
Crossref
J.A. van Noord, J.-L. Aumann, E. Janssens, J.J. Smeets, J. Zaagsma, A. Mueller & P.J.G. Cornelissen. (2010) Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respiratory Medicine 104:7, pages 995-1004.
Crossref
Crossref
Donald P Tashkin. (2010) Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Current Opinion in Pulmonary Medicine 16:2, pages 97-105.
Crossref
Crossref
Donald P. Tashkin, Nicola A. Hanania, Joe McGinty, Kimberly Denis-Mize & Imtiaz Chaudry. (2009) Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Advances in Therapy 26:11, pages 1024-1034.
Crossref
Crossref
Nicola A. Hanania, Ahmad Boota, Edward Kerwin, LaTanya Tomlinson & Kimberly Denis-Mize. (2009) Efficacy and Safety of Nebulized Formoterol as Add-on Therapy in COPD Patients Receiving Maintenance Tiotropium Bromide. Drugs 69:9, pages 1205-1216.
Crossref
Crossref